Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.52 |
| ▸ | CNR1 | P21554 | 10/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440064 | 0.81 | CNR2 (0.40) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL6486173 | 0.80 | P2RX7 (0.54) | P2RX7NPC1RAB9AKMT2ACYP2C9 | |
| SCHEMBL6419777 | 0.79 | CNR2 (0.40) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL13962868 | 0.77 | CNR2 (0.46) | CNR2CNR1P2RX7NPC1RAB9A | |
| SCHEMBL15401441 | 0.76 | GRM4 (0.46) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL9736861 | 0.76 | SMN1; SMN2 (0.50) | CNR2CNR1NPC1KMT2A | |
| SCHEMBL6415759 | 0.76 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL15401439 | 0.74 | ALDH1A1 (0.48) | CNR2CNR1P2RX7NPC1RAB9A | |
| SCHEMBL14082202 | 0.73 | TRPV1 (0.60) | CNR2CNR1NPC1RAB9AATM | |
| SCHEMBL9307990 | 0.73 | KDM4E (0.53) | CNR2CNR1NPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1278167-A | Amide derivatives | SUMITOMO PHARMA (JP) | 2000-12-27 | — | — | CN | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | CNR2 183/4885CNR1 206/4885P2RX7 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.